A novel blood test can accurately identify ALS patients at early stages, enabling faster diagnosis and earlier treatment.
A therapeutic antibody has the potential to significantly alleviate the burden of heart failure and cardiovascular disease.
Targeting and eliminating senescent "zombie cells" can significantly extend lifespan and improve health in aged mice.
Plasma phosphorylated tau protein (p-tau217) testing can accurately identify preclinical Alzheimer's disease in cognitively unimpaired adults, potentially streamlining clinical trial recruitment and reducing the need for more invasive diagnostic tests.
Levels of neurofilament light chain (Nfl) may serve as an early biomarker for chemotherapy-induced peripheral neurotoxicity (CIPN), providing clinicians with valuable information to guide treatment decisions and mitigate long-term nerve damage.
A unique autoantibody signature is detectable in the blood of people with multiple sclerosis up to 5 years before symptom onset, which could aid in early diagnosis and treatment.
Inhibiting the cell death pathway of necroptosis can reduce the excessive inflammatory response and mortality in severe influenza infections.
Computer vision technology can effectively identify subtle behavioral and physical changes in experimental mice, enabling continuous, accurate, and efficient monitoring of vaccine side effects.
Highly clinically cited biomedical papers have distinct advantages over medium and lowly clinically cited papers in accumulating clinical citations, both in the initial stage (from 0 to 1st clinical citation) and the build-up stage (from 1st to Nth clinical citation). Biomedical papers closer to clinical science more easily receive clinical citations than papers closer to basic science.
Artificial intelligence has identified two plant-derived bioactive compounds that may activate the glucagon-like-peptide-1 receptor (GLP-1R), a target for existing weight loss drugs, potentially offering natural alternatives with fewer side effects and oral administration.